Vita 34 Ag Stock Net Income
| VTIAF Stock | USD 6.38 0.00 0.00% |
As of the 28th of January, VITA 34 has the Risk Adjusted Performance of (0.09), coefficient of variation of (812.40), and Variance of 1.19. Compared to fundamental indicators, the technical analysis model makes it possible for you to check available technical drivers of VITA 34 AG, as well as the relationship between them. Please validate VITA 34 AG standard deviation, as well as the relationship between the treynor ratio and kurtosis to decide if VITA 34 is priced fairly, providing market reflects its prevalent price of 6.38 per share. Given that VITA 34 AG has variance of 1.19, we advise you to double-check VITA 34 AG's current market performance to make sure the company can sustain itself next year.
VITA 34's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing VITA 34's valuation are provided below:VITA 34 AG does not currently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. VITA |
VITA 34 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to VITA 34's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of VITA 34.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in VITA 34 on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding VITA 34 AG or generate 0.0% return on investment in VITA 34 over 90 days. VITA 34 is related to or competes with Lumos Diagnostics, HLS Therapeutics, Jushi Holdings, Hofseth BioCare, Senzime AB, Avita Medical, and Kintor Pharmaceutical. VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germ... More
VITA 34 Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure VITA 34's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess VITA 34 AG upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.20) | |||
| Maximum Drawdown | 8.86 |
VITA 34 Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for VITA 34's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as VITA 34's standard deviation. In reality, there are many statistical measures that can use VITA 34 historical prices to predict the future VITA 34's volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.25) | |||
| Treynor Ratio | (0.78) |
VITA 34 January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.77) | |||
| Mean Deviation | 0.2643 | |||
| Coefficient Of Variation | (812.40) | |||
| Standard Deviation | 1.09 | |||
| Variance | 1.19 | |||
| Information Ratio | (0.20) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.25) | |||
| Treynor Ratio | (0.78) | |||
| Maximum Drawdown | 8.86 | |||
| Skewness | (8.12) | |||
| Kurtosis | 66.0 |
VITA 34 AG Backtested Returns
VITA 34 AG owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.13, which indicates the firm had a -0.13 % return per unit of risk over the last 3 months. VITA 34 AG exposes sixteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate VITA 34's Coefficient Of Variation of (812.40), variance of 1.19, and Risk Adjusted Performance of (0.09) to confirm the risk estimate we provide. The entity has a beta of 0.18, which indicates not very significant fluctuations relative to the market. As returns on the market increase, VITA 34's returns are expected to increase less than the market. However, during the bear market, the loss of holding VITA 34 is expected to be smaller as well. At this point, VITA 34 AG has a negative expected return of -0.14%. Please make sure to validate VITA 34's treynor ratio, and the relationship between the standard deviation and kurtosis , to decide if VITA 34 AG performance from the past will be repeated at some future point.
Auto-correlation | 0.00 |
No correlation between past and present
VITA 34 AG has no correlation between past and present. Overlapping area represents the amount of predictability between VITA 34 time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of VITA 34 AG price movement. The serial correlation of 0.0 indicates that just 0.0% of current VITA 34 price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, VITA 34 AG reported net income of (3.67 Million). This is 101.07% lower than that of the Healthcare sector and significantly lower than that of the Medical Care Facilities industry. The net income for all United States stocks is 100.64% higher than that of the company.
VITA Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VITA 34's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of VITA 34 could also be used in its relative valuation, which is a method of valuing VITA 34 by comparing valuation metrics of similar companies.VITA 34 is currently under evaluation in net income category among its peers.
VITA Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.0503 | |||
| Profit Margin | (0.18) % | |||
| Operating Margin | (0.15) % | |||
| Current Valuation | 146.63 M | |||
| Shares Outstanding | 15.83 M | |||
| Shares Owned By Insiders | 67.61 % | |||
| Shares Owned By Institutions | 15.38 % | |||
| Price To Earning | 51.47 X | |||
| Price To Book | 3.67 X | |||
| Price To Sales | 2.18 X | |||
| Revenue | 28.42 M | |||
| Gross Profit | 12.44 M | |||
| EBITDA | 985 K | |||
| Net Income | (3.67 M) | |||
| Cash And Equivalents | 25.4 M | |||
| Cash Per Share | 1.61 X | |||
| Total Debt | 10.93 M | |||
| Debt To Equity | 0.84 % | |||
| Current Ratio | 0.79 X | |||
| Book Value Per Share | 2.25 X | |||
| Cash Flow From Operations | 2.73 M | |||
| Earnings Per Share | 0.07 X | |||
| Number Of Employees | 775 | |||
| Beta | 0.79 | |||
| Market Capitalization | 110.48 M | |||
| Total Asset | 177.95 M | |||
| Z Score | 6.0 | |||
| Net Asset | 177.95 M |
About VITA 34 Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VITA 34 AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VITA 34 using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VITA 34 AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in VITA Pink Sheet
VITA 34 financial ratios help investors to determine whether VITA Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in VITA with respect to the benefits of owning VITA 34 security.